TRIM21 and autoimmune disease: SSA autoantibodies, originally discovered in the 1960s1, are important clinical biomarkers for the diagnosis of a number of autoimmune diseases including myositis, scleroderma, systemic lupus erythematosus, and Sjögren’s syndrome2.